Cargando…

4-1BB: A promising target for cancer immunotherapy

Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Alyssa Min Jung, Nemeth, Macy Rose, Lim, Seung-Oe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515902/
https://www.ncbi.nlm.nih.gov/pubmed/36185242
http://dx.doi.org/10.3389/fonc.2022.968360
_version_ 1784798593777926144
author Kim, Alyssa Min Jung
Nemeth, Macy Rose
Lim, Seung-Oe
author_facet Kim, Alyssa Min Jung
Nemeth, Macy Rose
Lim, Seung-Oe
author_sort Kim, Alyssa Min Jung
collection PubMed
description Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines, and T cell transfer therapies that serve the purpose of harnessing the body’s immune system to combat disease. Of these different types, immune checkpoint blockades that target coinhibitory receptors, which dampen the body’s immune response, have been widely studied and established in clinic. In contrast, however, there remains room for the development and improvement of therapeutics that target costimulatory receptors and enhance the immune response against tumors, one of which being the 4-1BB (CD137/ILA/TNFRSF9) receptor. 4-1BB has been garnering attention as a promising therapeutic target in the setting of cancer, amongst other diseases, due to its broad expression profile and ability to stimulate various signaling pathways involved in the generation of a potent immune response. Since its discovery and demonstration of potential as a clinical target, major progress has been made in the knowledge of 4-1BB and the development of clinical therapeutics that target it. Thus, we seek to summarize and provide a comprehensive update and outlook on those advancements in the context of cancer and immunotherapy.
format Online
Article
Text
id pubmed-9515902
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95159022022-09-29 4-1BB: A promising target for cancer immunotherapy Kim, Alyssa Min Jung Nemeth, Macy Rose Lim, Seung-Oe Front Oncol Oncology Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines, and T cell transfer therapies that serve the purpose of harnessing the body’s immune system to combat disease. Of these different types, immune checkpoint blockades that target coinhibitory receptors, which dampen the body’s immune response, have been widely studied and established in clinic. In contrast, however, there remains room for the development and improvement of therapeutics that target costimulatory receptors and enhance the immune response against tumors, one of which being the 4-1BB (CD137/ILA/TNFRSF9) receptor. 4-1BB has been garnering attention as a promising therapeutic target in the setting of cancer, amongst other diseases, due to its broad expression profile and ability to stimulate various signaling pathways involved in the generation of a potent immune response. Since its discovery and demonstration of potential as a clinical target, major progress has been made in the knowledge of 4-1BB and the development of clinical therapeutics that target it. Thus, we seek to summarize and provide a comprehensive update and outlook on those advancements in the context of cancer and immunotherapy. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9515902/ /pubmed/36185242 http://dx.doi.org/10.3389/fonc.2022.968360 Text en Copyright © 2022 Kim, Nemeth and Lim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kim, Alyssa Min Jung
Nemeth, Macy Rose
Lim, Seung-Oe
4-1BB: A promising target for cancer immunotherapy
title 4-1BB: A promising target for cancer immunotherapy
title_full 4-1BB: A promising target for cancer immunotherapy
title_fullStr 4-1BB: A promising target for cancer immunotherapy
title_full_unstemmed 4-1BB: A promising target for cancer immunotherapy
title_short 4-1BB: A promising target for cancer immunotherapy
title_sort 4-1bb: a promising target for cancer immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515902/
https://www.ncbi.nlm.nih.gov/pubmed/36185242
http://dx.doi.org/10.3389/fonc.2022.968360
work_keys_str_mv AT kimalyssaminjung 41bbapromisingtargetforcancerimmunotherapy
AT nemethmacyrose 41bbapromisingtargetforcancerimmunotherapy
AT limseungoe 41bbapromisingtargetforcancerimmunotherapy